Teleborsa: distribution and commercial use strictly prohibited

EMARKET SDIR

CERTIFIED



COMPANY PRESENTATION

8th Annual Polytems Hir Italian Day in Frankfurt

January 24th, 2024



Member of Euronext Tech Leaders



EURONEXT

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.



Teleborsa: distribution and commercial use strictly prohibited

SDIR certified





1.0verview

2. Markets and Growth drivers

3. Our strategy and market approach

4. Financial Highlights

5.Current Outlook

6.Multiples & Comparables

Teleborsa: distribution and commercial use strictly prohibited EMARKET SDIR CERTIFIED



OVERVIEW



OVERVIEW

A PRIMARY PLAYER PROVIDING MEDICAL, INDUSTRIAL AND CONSERVATION LASER SOLUTIONS WORLDWIDE



World Class Hi-Tech company

Hi-Tech industrial group providing laser solutions with proprietary technologies and know how developed over 40 years



Listed on Euronext STAR Milan of Italian Stock Exchange since year 2000 and member of Euronext Tech Leaders



Within Worldwide leaders in its space



Active worldwide on several laser application segments and markets...



...progressively widening its worldwide presence achieving continuous growth over the years

SDIR



WE CREATE LIGHT, ENERGY, WAVES



MEDICAL

Our energy based systems improve people's well-being and life quality.

In the SURGICAL SECTOR, our minimally invasive technology systems minimize pain, side effects and risks of surgical procedures and hospitalization days.

In the AESTHETIC SECTOR, our systems satisfy the growing desire of individuals to improve their appearance also reducing pathological or painful imperfections.



INDUSTRIAL

Our LASER CUTTING and MARKING SYSTEMS Improve the productivity of our customers manufacturing plants also limiting the environmental impact of manufacturing processes minimizing waste, fumes generated by the process, use of chemical additives, and allowing to eliminate the need for inks, solvents or glues within the process.



CONSERVATION

Our LASER SYSTEMS PRESERVE artworks of the universal heritage of our communities.



ENVIRONMENT



2 Photovoltaic systems active in 21

4 New plants installed in 22



OUR HISTORY

<u>80s</u>

Production of $\mathrm{CO}_{\rm 2}$ lasers for dermatology, surgery and therapy

1981

Incorporation of El.En.S.n.c

<u>90s</u>

Development of short pulse Nd:YAG lasers for dentistry and minimally invasive surgery treatments

○1990 - 1993

Incorporation of **Deka MELA S.r.l., Lasit S.p.A.** e **Cutlite Penta S.r.l.**

<u>1998</u>

Smartepil (Deka Mela S.r.l.) - first long pulse Nd:Yag laser for dermatology and hair removal

<u>2000</u>

El.En.S.p.A. listed on the italian stock market

>2002

Smartlipo (Deka Mela S.r.l.**laserlipolisi**°: localized removal of adipose deposits with minimally invasive treatment

Acquisition of Cynosure Inc.

2003

Smartxide DOT^{*} Therapy (Deka Mela S.r.l.) dermatological surgery, anti-aging treatments, removal of pigmented lesions and scars

Acquisition of Asclepion GmbH

2004 Acquisition of Quanta System

Acquisition of Asa

Cynosure IPO on Nasdaq



Incorporation of a JV in China: Wuhan Penta Chutian Co.Ltd

Incorporation of Cutlite Do Brasil Alta Tecnologia Ltda

<u>2008 </u>

Mediostar XT (Asclepion GmbH) esthetics and hair removal.

Industrial sector El.En.– creation of the BLADE RF CO₂ **BLADE RF** laser sources family

Litho (Quanta System S.p.A.) surgical, treatment of kidney stones

2009

Plus RF (Cutlite Penta S.r.l.) with RF El.En. sources for metacrilate and wood cutting systems

Incorporation of Esthelogue S.r.l.

2010

Smartxide² (Deka Mela S.r.l.) laser system with CO₂ radio frequency (RF) laser sources for dermatological surgery and aesthetics

2011

Mediostar Next (Asclepion GmbH) aesthetics, hair removal



OUR HISTORY

<u>2012</u>

Monna Lisa Touch[™] (Deka Mela S.r.l.) for the treatment of vaginal atrophy

Cyber (Quanta System S.p.A.) surgery, Lithotripsy and BPH

<u>2013</u>

Incorporation of second JV Penta Laser Equipment (Wenzhou) Co.Ltd

<u>2015</u>

Bolt (Penta Chutian e Wenzhou - China) enhanced system for laser metal cutting

Discovery Pico (Quanta System S.p.A.) tattoo and pigmented lesions removal and dermatological treatments

HIROTT (ASA S.r.l.) painful pathologies of the muscle and skeleton

Fiber Plus (Cutlite Penta S.r.l.) first metal cutting laser system equipped with fiber laser source

<u>2016</u>

Motus AX with Moveo (Deka Mela S.r.l.) hair removal, removal of pigmented lesions

Juliet[®] (Asclepion GmbH) for the treatment of vaginal atrophy

Deka M.E.L.A.S.r.l.and Quanta System S.p.A. join their commercial brand names into **Reinassance**° for the Italian market

Industrial sector ${\rm RF}~{\rm 1222}\,{\rm CO}_2\,{\rm RF}$ laser source "The Big Boy"

ONDA Coolwaves[•](Deka Mela S.r.l.) the first microwaves technology system for body contouring

<u>2019</u>

The Chinese subsidiary Penta Laser Equipment (Wenzhou) Co. Ltd incorporates **Penta Laser Technology (Shangdong) Co. Ltd**

Acquisition by Quanta System of Galli S.r.l. a precision mechanical components manufacturing facility.

<u>2020</u>

Schwarzy (magnetotherapy) Red Touch (dermatology) Again (hair removal) Dr.Arnold (magnetotherapy)

2021

Lasit Laser Polska incorporated by Lasit in Poland

Glide (dermatology) Chrome Laser Station (dermatology)

<u>2022</u>

Lasit Laser Iberica incorporated by Lasit in Spain

Acquisition by Penta Laser Zhejiang of **Shenzhen KBF Laser Tech Co. Ltd**

2023


Lasit Laser Deutschland GmbH incorporated by Lasit in Germany


Lasit Laser UK Ltd incorporated by Lasit in UK

EMARKET SDIR certified



EL.EN. WORLDWIDE





Teleborsa: distribution and commercial use strictly prohibited



MARKETS AND GROWTH DRIVERS



LASER SURGERY MARKET TRENDS

MINIMALLY INVASIVE SURGERIES:

- Painless procedures
- Lower risks and side effects
- Shorter hospital stays/Faster recovery
- Savings by Private & National Health Systems
- Attractive ROI for surgical services providers
- Rapidly Growing Urology laser market





MEDICAL AESTHETICS MARKET TRENDS

- Aging demographics and increasing focus on improving appearance and youthfulness;
- Growing interest in non-invasive or minimally invasive procedures and awareness of energybased aesthetic treatments
- Growing global obesity rate
- Reductions in procedure costs, attracting a broader patient base
- Normalization and social acceptance of cosmetic procedures
- Rapid growth expected





MARKET RESEARCHES GROWTH ESTIMATES

GLOBAL MEDICAL LASER MARKET

- Mordor Intelligence
- Fortune business insights
- Global Market Insights
- Research and Markets

CAGR 13,4% to 2028 CAGR 13,1% to 2030 CAGR 14,5% to 2032 CAGR 13,2% to 2030

With an estimated market size of \simeq \$5 Bln in 2021 including:

- Ophthalmology
- Dermatology
- Aesthetics
- Surgical
- Synecology Urology
- Cardiovascular
- Dentistry

EXPECTED GROWTH IN COSMETIC MARKET

- Research and Markets
- The business research company

CAGR 15,2% to 2027 CAGR 19,1% to 2027



SDIR certified





INDUSTRIAL LASER MARKET TREND



Laser cutting applications:

- Laser power increase + Cost reduction: enhanced flexibility, productivity and quality standards in manufacturing processes
- New application verticals
- Building and construction





- Products identification and traceability
- Minimal environmental impact

Laser processing market:

- Size: \$17,48 billion in 2021
- Expected CAGR to 2030: 9,1%

Source: Grand view research

Teleborsa: distribution and commercial use strictly prohibited



OUR STRATEGY AND MARKET APPROACH

OUR KNOWLEDGE



Technical Knowledge



El	ectr	oni	ics





Photonics

Mechanics



Fluid dynamics



Nower electronics

Sof







Application Expertise

Aesthetics



Surgery



Dermatology



Physiotherapy




Cutting




Marking

Art Conservation

THE LASER ADVANTAGE









Flexibility

- Speed
- Power
- Precision
- Selectivity
- Effectiveness



 Continuous investment in R&D: maintaining the unmatched wideness of our product range by innovating existing technologies and developing new ones

Cooperation with primary research institutions and KOL'S

Excellent knowledge of the target markets based on the widespread and loyal distribution network created over the years

Ability to continuously update the laser technology of our wide product range

Focus on innovative products release, technical support and continuous training to our customers

Multi brand approach

ELEN[®]



CERTIFIE

WIDE RANGE OF PRODUCTS IN MEDICAL SECTOR **ELEN**[®]



un volailaito d

EMARKET SDIR CERTIFIED

.. AND IN INDUSTRIAL SECTOR

Cutting





Art Conservation









distribution and some

Marking

use strictly prohibited

EMARKET SDIR

CERTIFIED











OUR PRODUCTS

ELEN[®]

atviath



Teleborsa: distribution and commercial use strictly prohibited



FINANCIAL HIGHLIGHTS



INCOME STATEMENT – FY 2022

ELEN^{**}

Euro '000	31/12/21	%	31/12/22	%	Var. %
Medical	311.290	54,5%	382.063	56,7%	22,7%
Industrial	260.112	45,5%	291.518	43,3%	12,1%
Revenues	571.402	100,0%	673.581	100,0%	17,9%
Gross margin	212.073	37,1%	249.695	37,1%	17,7%
Operating Expenses	47.812	8,4%	56.250	8,4%	17,6%
Staff espenses	84.170	14,7%	98.194	14,6%	16,7%
EBITDA	80.091	14,0%	95.251	14,1%	18,9%
Depr., amort., accruals	15.234	2,7%	14.250	2,1%	-6,5%
EBIT	64.858	11,4%	81.001	12,0%	24,9%
Net financ.income(charges)	1.752	0,3%	(1.934)	-0,3%	
Other income (expense) net	(185)	0,0%	(79)	0,0%	-57,5%
EBT	66.424	11,6%	78.988	11,7%	18,9%
Income taxes	17.300	3,0%	19.953	3,0%	15,3%
Minorities	3.688	0,6%	3.925	0,6%	6,4%
	45.436	8,0%	55.111	8,2%	21,3%
	73,730	0,070		0,270	22,370

BALANCE SHEET– FY 2022

Euro '000	31/12/21	31/12/22	Var.%
		restated	
Total non current assets	136.648	165.786	21,3%
Net Working Capital	144.641	200.536	38,6%
Other receivables/payables ST	(91.278)	(80.154)	-12,2%
Net financial position	115.766	75.363	-34,9%
Long term liabilities	18.076	18.077	0,0%
Net Equity	287.701	343.455	19,4%
Net capital employed	171.935	268.092	55,9%
Net Working Capital on sales	25,3%	29,8%	
ROCE	37,7%	30,2%	
(EBIT/Net capital employed)			
Operating Capex	23.150	28.514	


EMARKET SDIR certified


Income Statement – 9M 2023

ELEN[®]


Euro '000	30/09/22	%	30/09/23	%	Var. %
	unaudited		unaudited		
Medical	270.529	55,9%	287.954	58,4%	6,4%
Industrial	213.820	44,1%	205.057	41,6%	-4,1%
Revenues	484.348	100,0%	493.011	100,0%	1,8%
Gross margin	179.496	37,1%	187.211	38,0%	4,3%
Operating Expenses	41.511	8,6%	44.393	9,0%	6,9%
Staff espenses	70.421	14,5%	80.938	16,4%	14,9%
EBITDA	67.564	13,9%	61.880	12,6%	-8,4%
Depr., amort., accruals	9.640	2,0%	10.102	2,0%	4,8%
EBIT	57.924	12,0%	51.778	10,5%	-10,6%
Net financ.income(charges)	(7)	0,0%	(866)	-0,2%	13078,8%
Other income (expense) net	3	0,0%	(42)	0,0%	
EBT	57.920	12,0%	50.870	10,3%	-12,2%
	31/12/22		30/09/23 unaudited		
Net financial position	75.363		32.089		

CERTIFIED






Q3




CERTIFIED


ELEN Revenue breakdown by business



Revenue breakdown by area

ELEN^{**}





EMARKET SDIR

CERTIFIED

Teleborsa: distribution and commercial use strictly prohibited



CURRENT OUTLOOK





Revenue 2023 > Revenue 2022



Teleborsa: distribution and commercial use strictly prohibited



MULTIPLES & COMPARABLES



Stockholder's Equity per share	4,5	
Price / Book Value Adj.	2,1	
EV /EBIT (90% EBIT)	11,2	
EV / Sales (90% Sales)	1,2	
El.En. Market Cap.	748,5 @	€ 9,36
Net financial position	32,1 @	30/09/23
Financial investments m/l term	23,6 @	30/09/23
Enterprise Value	692,7	



COMPARABLES


Sept. 30th , 2023	_									
	Price on Jan.19,	Revenue	Var.%	EBIT	EBIT %	МК.Сар.	EV	EV/Sales	EV/EBIT	P/Book
Medical/Aesthetic	2024		Rev.					(*)	(*)	Value
Cutera (2)	\$3,03	\$116	-5%	\$(53)	-46%	\$60	\$267	1,1	n.a.	n.a.
InMode	\$22,90	\$365	14%	\$144	40%	\$1.900	\$1.227	2,5	6,4	2,6
Beauty Health	\$2,39	\$301	13%	\$(113)	-37%	\$314	\$506	1,3	n.a.	3,5
Venus	\$1,35	\$58	-23%	\$(21)	-36%	\$7	\$86	1,1	n.a.	n.a.
Sisram Medical (2)	\$0,61	\$172	-2%	\$22	13%	\$285	\$271	0,8	6,2	0,6
Classys	€ 23,66	€ 94	25%	€ 48	51%	€ 1.532	€ 1.492	11,9	23,4	8,1
Industrial										
IPG Photonics Co.	\$99,31	\$989	-10%	\$203	21%	\$4.660	\$3.596	2,7	13,3	2,0
Han's Laser	¥18,15	¥9.344	-11%	¥599	6%	¥19.350	¥19.036	1,5	23,9	1,2
Bystronic (2)	CHF 437	CHF 468	3%	CHF 25	5%	CHF 797	CHF 410	0,4	8,1	1,1
El.En. (1)	€ 9,36	€ 493	2%	€ 52	11%	€ 748	€ 693	1,2	11,2	2,1

(1) EV and multiplies as for previous slide

(2) Financials on June 30th, 2023

(*) Revenue, Ebit and earnings annualized

CERTIFIED







CONTACTS

El.En. S.P.A. Enrico Romagnoli Investor Relations Manager tel. +39 055-8826807 E-mail: <u>finance@elen.it</u>

POLYTEMS HIR

Financial Communication, IR and Press Office **Bianca Fersini Mastelloni** - b.fersini@polytemshir.it **Silvia Marongiu** - <u>s.marongiu@polytemshir.it</u> Tel. +39 06-69923324